CSF-1 and its receptor in ovarian, endometrial and breast cancer.
暂无分享,去创建一个
[1] M. Duffy,et al. Urokinase plasminogen activator and prognosis in breast cancer , 1990, The Lancet.
[2] L. Yee,et al. Oncogene structure, function, and expression in breast cancer. , 1989, Seminars in diagnostic pathology.
[3] M. J. van de Vijver,et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.
[4] Inder M. Verma,et al. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus , 1986, Nature.
[5] F. Beuvon,et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. , 1994, Journal of the National Cancer Institute.
[6] F. Beuvon,et al. Expression of Colony‐Stimulating Factor‐1 and Its Receptor (the Protein Product of c‐fms) in Invasive Breast Tumor Cells , 1993, Annals of the New York Academy of Sciences.
[7] P. Nowell,et al. Origins of human cancer revisited , 1990, Cell.
[8] R. Lupu,et al. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.
[9] T. Tong,et al. Cancer statistics, 1991 , 1991, CA: a cancer journal for clinicians.
[10] J. Horiguchi,et al. CSF-1 and C-FMS gene expression in human carcinoma cell lines. , 1988, Biochemical and biophysical research communications.
[11] R. Kamen,et al. The human hematopoietic colony-stimulating factors. , 1987, Science.
[12] L. Rohrschneider,et al. Activation of the feline c-fms proto-oncogene: Multiple alterations are required to generate a fully transformed phenotype , 1988, Cell.
[13] B. Kacinski,et al. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. , 1995, Oncogene.
[14] T. Pawson,et al. The unique insert of cellular and viral fms protein tyrosine kinase domains is dispensable for enzymatic and transforming activities. , 1989, The EMBO journal.
[15] Robert A. Edwards,et al. Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. , 1989, The Yale journal of biology and medicine.
[16] B. Binder,et al. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. , 1992, Cancer research.
[17] C. Willman,et al. Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1 , 1989, The Journal of experimental medicine.
[18] L. Lagasse,et al. Prognosis and treatment of endometrial cancer. , 1980, American journal of obstetrics and gynecology.
[19] W. Halsted. I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. , 1907, Annals of surgery.
[20] S. Chambers,et al. Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas in vitro , 1994, Steroids.
[21] J. Downing,et al. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential , 1988, Cell.
[22] W. Wiktor-Jedrzejczak,et al. A pregnancy defect in the osteopetrotic (op/op) mouse demonstrates the requirement for CSF-1 in female fertility. , 1991, Developmental biology.
[23] R. Bast,et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .
[24] A. Balmain,et al. Is colony‐stimulating factor‐1 a key mediator of breast cancer invasion and metastasis? , 1993, Molecular carcinogenesis.
[25] D. Stern,et al. EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.
[26] A. Harris,et al. Epidermal growth factor receptors in human breast cancer. , 1988, Cancer treatment and research.
[27] F. Galibert,et al. Nucleotide sequence and structural organization of the human FMS proto-oncogene. , 1989, Oncogene research.
[28] D. Stern,et al. Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[29] A. Ariza,et al. The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients. , 1990, International journal of radiation oncology, biology, physics.
[30] B. Kacinski,et al. Expression of transcripts for CSF-1 and for the "macrophage" and "epithelial" isoforms of the CSF-1R transcripts in human ovarian carcinomas. , 1994, Cancer detection and prevention.
[31] N. Deng,et al. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines. , 1992, Cancer research.
[32] S K Chambers,et al. Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. , 1993, American journal of obstetrics and gynecology.
[33] U. Puistola,et al. Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen. , 1995, American journal of obstetrics and gynecology.
[34] B. Kacinski,et al. The first intron of human c-fms proto-oncogene contains a processed pseudogene (RPL7P) for ribosomal protein L7. , 1994, Genomics.
[35] L. Yee,et al. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. , 1991, Oncogene.
[36] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[37] M. Roussel,et al. Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. , 1986, The Journal of clinical investigation.
[38] J. Pollard,et al. Colony stimulating factor-1 stimulates Ishikawa cell proliferation and lipocortin II synthesis , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[39] F. Beuvon,et al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells? , 1990, Journal of cellular biochemistry.
[40] R. Camplejohn,et al. Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Robert A. Edwards,et al. High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. , 1988, International journal of radiation oncology, biology, physics.
[42] R. Arceci,et al. Apparent role of the macrophage growth factor, CSF-1, in placental development , 1987, Nature.
[43] L. Yee,et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. , 1990, The American journal of pathology.
[44] P Roth,et al. The biology of CSF-1 and its receptor. , 1992, Current topics in microbiology and immunology.
[45] D. Carter,et al. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. , 1992, Gynecologic oncology.
[46] P. Schwartz,et al. Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. , 1989, International journal of radiation oncology, biology, physics.
[47] M. Schmitt,et al. UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCER , 1989, The Lancet.
[48] H. Koeppen,et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[49] D. Stern,et al. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Bast,et al. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. , 1989, The Journal of clinical investigation.
[51] R. Kriz,et al. Human CSF-1: molecular cloning and expression of 4-kb cDNA encoding the human urinary protein. , 1987, Science.
[52] Rutledge Fn,et al. Epithelial carcinoma of the ovary:prognostic importance of histologic grade. , 1975 .
[53] D. Carter,et al. Expression of neu Antigen in Normal Lactating and Prepartum Mammary Epithelial Cells , 1995, The Journal of the Society for Gynecologic Investigation: JSGI.